Solvias Launches a New Center for Biologics and Cell Therapy in Research Triangle Park

Solvias Opens a New Center of Excellence for Biologics and Cell Therapy in RTP

In a significant expansion of its capabilities, Solvias, a renowned global provider of chemistry, manufacturing, and control (CMC) analytics, has inaugurated its new Center of Excellence in Research Triangle Park (RTP), North Carolina. This state-of-the-art facility marks Solvias’ commitment to developing transformative treatments for cancer and rare diseases, further bolstering its global network.

Overview of the New Facility

The new center encompasses an impressive area of 4,600 square meters and serves as Solvias’ flagship site in North America for analytical services related to large molecules. Designed with the aim of accelerating the development and commercialization of innovative biologics, the center is a critical asset in the biopharmaceutical landscape.

Job Creation and Operational Phases

This facility is projected to create approximately 200 new jobs over the next three years within the Raleigh-Durham region. The rollout of the center will occur in two distinct phases:
1. Phase 1: This initial phase includes 1,900 square meters of space dedicated to cGMP release testing based on cell-based potency and molecular analysis, which is already operational.
2. Phase 2: The second phase, expected to launch in July 2025, will introduce an additional 2,800 square meters offering comprehensive stability testing and advanced biophysical characterization capabilities.

Cutting-Edge Technology

Equipped with the latest analytical instruments, laboratory automation, and advanced digital management systems, Solvias’ new center is poised to deliver extensive GMP testing for cell and gene therapies, monoclonal antibodies (mAbs), and other biological products. This facility will support processes ranging from preclinical to commercial release of these therapies, aiming to significantly enhance patient outcomes worldwide.

Vision and Leadership Commitment

Archie Cullen, the Chief Executive Officer of Solvias, emphasized the importance of this new center, stating, "This Center of Excellence in RTP is a milestone in the global growth of Solvias. By combining our team's expertise with advanced technology, we aspire to set a new standard in delivering high-quality, reliable analytical support. We are honored to partner with our clients to bring groundbreaking therapies to patients across the globe."

Ilya Koltover, Chief Commercial Officer at Solvias, expressed that the center would serve as a cornerstone of bio-pharmaceutical innovation in the United States. "We are focused on using our analytical expertise to help our clients succeed. By recruiting the best talent, we will become technical partners for our clients, assisting them in bringing therapies to market swiftly and efficiently."

A Global Network

With the opening of this facility, Solvias now operates six Centers of Excellence globally, further solidifying its commitment to the biopharmaceutical industry in North America. To learn more about Solvias and its new Center of Excellence in RTP, visit solvias.com.

About Solvias

Solvias specializes in providing CMC analytics to the bioscience industry. With decades of regulatory expertise in small molecules, biologics, and cell and gene therapies, Solvias offers comprehensive solutions from raw material testing to drug release and API development. Headquartered near Basel, Switzerland, the company adheres to the highest industry standards, including ISO, GMP, GLP, and FDA regulations.